Social Media Ideas for Vxrt

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

V2X Q2 2026 Earnings Preview

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution

CEO James Foster to discuss the Company's financial and strategic position, commercial strategy for ImmuneSelect and development plans for ViraxImmuneâ„¢Webinar to include an overv...

V2X, Inc. (VVX) Q2 2026 Earnings Call Transcript

Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts

Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

Is This Biotech Stock a Buy Near Its 52-Week High?

It's been a volatile year for the company, but don't let that scare you away.

Is This Biotech Stock a Buy After Its Massive Rally?

This biotech has a powerful growth story, but one competitive threat could reshape the entire investment case before the payoff arrives.

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

Recursion (RXRX) Q2 2026 Earnings Call Transcript

AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

The biotech's diversification efforts continue.

Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet

Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on...

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Ta...

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

V2X: Why The Post-Earnings Pullback Makes Sense

Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher?

The pharma stock is up around 17% this year.

Vera Therapeutics

Vera Therapeutics Anonymous (not verified) Wed, 07/01/2026 - 06:05 field_thread_url https://cafepharma.com/boards/threads/vera-therapeutics.713115/...

Is RTX Corporation (RTX) A Good Stock To Buy Now?

This GLP-1 Stock Could Double by 2030. Here's Why

Investors need to ask tough questions before initiating a position in this biotech company.

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?